Russian Federation expects India to approve Sputnik V vaccine for use soon

Clay Curtis
February 3, 2021

Serious side effects were rare in both groups and four deaths were reported, although none were considered to be the result of the vaccine.

The government is seeking a deal with Russian Federation that would enable it to manufacture the Sputnik V vaccine in Argentina, the country's new envoy to Moscow has confirmed.

Some early results on it were published in September, but participants had only been followed for 42 days and there was no comparison group.

This means "another vaccine can now join the fight to reduce the incidence of COVID-19", the statement added.

The people in the trial were given PCR Covid-19 tests when they received the second shot.

The calculation is based on the analysis of 78 confirmed cases of Covid-19 identified in the placebo group (62 cases) and in the vaccine group (16 cases).

There were 2,144 volunteers over 60 in the Sputnik V trial and the shot was shown to be 91.8pc effective when tested on this older group, with no serious side-effects reported that could be associated with the vaccine, The Lancet summary said. Developers of the vaccine cited ethical concerns about using placebo shots. This is the same type of vaccine being developed by Johnson & Johnson and AstraZeneca.

Just 16 out of 16,500 people given the two-dose jab - dubbed Sputnik V - developed symptoms, while no-one died from the disease or needed hospital treatment.

The vaccine's production has been funded by the Russian Direct Investment Fund (RDIF), which is also responsible for selling it globally.

Reacting to the findings, Dr Julian Tang, a clinical virologist at the University of Leicester, said: 'This Russian Sputnik V adenovirus-vectored vaccine. appears even more effective after two doses (91.6 per cent) than the Oxford/AstraZeneca vaccine standard dose regimen.

Reddit Is Coming For Silver. A Short Squeeze? Unlikely
For comparison, Pan American uses a silver price assumption of about US18.50 an ounce for long-term planning, said Steinmann. The near-term bullish breakout in silver prices may be the start of the next leg higher in this multi-year bottoming effort.

Alexander Edwards, an associate professor in Biomedical Technology at the University of Reading, said the trial might help provide evidence to this theory of immune response.

He said that, with two identical shots, it's possible that the immune system doesn't get as big a boost from the second injection.

Sputnik V was rolled out in a large-scale vaccination campaign in Russian Federation in December, with doctors and teachers the first in line. Last month, Putin ordered the effort to be expanded and for mass immunisations to start. Some Russian media questioned the number, suggesting that the rollout has been much slower, with many Russian regions reporting small numbers of vaccinations.

The vaccine is already approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Guinea, Tunisia, Armenia and the Palestinian territories.

Algeria will begin producing the Sputnik V vaccine "within the coming weeks", Kamel Mansouri, the head of Algeria's national agency for pharmaceuticals, said Tuesday.

Hungarian health authorities were the first in the European Union to approve the vaccine on January 21, but the National Public Health Center must still give its final approval before shots are distributed to the public.

The European Commission said Monday (1 February) the shortfall in deliveries from Anglo-Swedish firm AstraZeneca had forced it to recalibrate its early coronavirus vaccination strategy. The Russian government has said that a third vaccine named CoviVac is expected to be approved this month too. German Chancellor Angela Merkel said that all COVID-19 vaccines would be welcome in the EU once authorised by the European Medicines Authority.

Russian Federation approved the Sputnik V vaccine for emergency use in August 2020, becoming the first country in the world to approve a coronavirus vaccine.

"The aim is to make sure that we can deliver supplies very quickly, i.e., the day on which the vaccine gets the green light", he told a press conference.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER